Last updated: May 24, 2026
Suppliers for Fluorodeoxyglucose F-18 (FDG F-18): Who Makes It, How It’s Sourced, and What to Benchmark for Purchase
Fluorodeoxyglucose F-18 (FDG F-18) is supplied through (1) centralized U.S. and international PET radiopharmaceutical manufacturers that prepare doses from cyclotron-produced F-18 and (2) hospital-owned or partner cyclotron operations that contract for radiochemical synthesis and dose dispensing. The practical supplier set for procurement is dominated by large radiopharmacy networks that hold U.S. PET drug manufacturing authorizations and distribute F-18 FDG doses to imaging sites.
Who supplies Fluorodeoxyglucose F-18 (FDG F-18) in the US market?
Core supplier categories
-
Radiopharmaceutical manufacturers (dose production + distribution)
These companies run PET manufacturing under U.S. FDA radiopharmaceutical facility authorizations (commonly using centralized synthesis, then regional distribution).
-
Regional PET radiopharmacies and dose distributors
Some suppliers operate regional dispensing sites under manufacturing or repackaging/distribution roles tied to an authorized production site.
-
Cyclotron-linked internal supply (hospital or health system)
Large health systems sometimes produce F-18 internally and contract with radiochemistry teams for synthesis and dispensing. This reduces single-source procurement exposure but adds operational and regulatory complexity.
What buyers should benchmark
- U.S. distribution coverage and cold-chain logistics for same-day or time-critical deliveries
- Batch capacity (number of doses per day/week) under realistic F-18 generator and cyclotron schedules
- Staffing and synthesis slot availability for weekday scheduling and emergency fill
- Whether the supplier is vertically integrated (F-18 production + FDG synthesis) or relies on third-party F-18 supply
- Documented continuity plans for cyclotron downtime and F-18 shortages
- Labeling and specification alignment to the target FDG formulation in procurement contracts
Which companies sell FDG F-18 doses to hospitals and imaging centers?
US procurement reality
FDG F-18 dosing is typically purchased from radiopharmaceutical manufacturers and distributors that supply the majority of U.S. PET centers. In practice, procurement lists are built from:
- suppliers that can deliver to local distribution zones on a consistent schedule
- organizations listed as distributors in radiopharmacy networks and GPO arrangements
- health-system contracts with named radiopharmaceutical vendors
Typical supplier list structure used in procurement
- National manufacturer brand(s) covering multiple regions
- Regional distributor or radiopharmacy partner names tied to the same underlying production source
- Alternate authorized suppliers used for bid cycles or contingency
How is FDG F-18 supplied: cyclotron production versus generator supply?
FDG F-18 depends on F-18 produced by cyclotrons (the isotope is not generator-supplied in the same way as technetium-99m). Supply chain mapping usually separates:
- F-18 production (cyclotron via proton irradiation of target material)
- radiochemical synthesis (automated module or synthesis cassette-based)
- quality control and release (radionuclidic identity, radiochemical purity, sterility assurance workflow)
- dose dispensing and distribution (time-windowed delivery to preserve activity)
Procurement implication
The “bottleneck” is often cyclotron time and F-18 target logistics rather than synthesis capacity alone during peak demand windows (scanner schedules, radiopharmacy throughput, and national imaging demand).
What delivery and availability terms matter most for FDG F-18?
Procurement terms that materially affect operational readiness:
- delivery cadence (daily vs. multiple-times-per-day schedules)
- activity strength ranges and packaging configuration (pre-measured syringes vs. multi-dose vials)
- time-in-transit constraints and window guarantees
- emergency allocation rules during F-18 production interruptions
- lot release lead times and acceptance testing expectations
Operational readiness checklist for buyers
- Confirm the supplier’s average and peak dose production capacity per day
- Require explicit contingency pathways if a shipment is late or activity falls below target at delivery
- Define how “activity on arrival” is handled (replacement vs. credit vs. reconstitution)
- Confirm whether the supplier can support high-throughput days and weekend schedules
What do FDA regulations and compounding rules mean for FDG F-18 supply?
FDG F-18 is a radiopharmaceutical with manufacturing and distribution obligations under FDA’s radiopharmaceutical quality system expectations. Buyers should expect suppliers to provide:
- drug product specs aligned to FDG F-18 labeling
- batch documentation and release criteria
- assurance of compliance with current good manufacturing practice for PET drug manufacturing operations
Commercial risk link
Supply continuity is influenced by how many authorized manufacturing sites exist for the product in a given region and whether those sites have capacity redundancy.
Which suppliers are best for redundancy if FDG F-18 shortages occur?
Supplier redundancy design
A resilient sourcing strategy typically uses:
- primary supplier with the highest schedule reliability and local distribution proximity
- secondary supplier that is still authorized for regional coverage even if the primary cyclotron schedule slips
- third backup for extreme events where secondary allocation is exhausted
What to evaluate in vendor qualification
- allocation policy during national shortages
- ability to re-route shipments across distribution hubs
- historical performance during documented demand surges
- documented cyclotron and target contingency plans
How does FDG F-18 supplier selection compare across national versus regional networks?
National manufacturers
- Pros: higher total capacity, multiple hubs, standardized QC and lot release
- Cons: freight lead times and allocation constraints can impact same-day availability
Regional radiopharmacy networks
- Pros: shorter delivery distance and tighter schedule adherence
- Cons: lower overall redundancy if the regional hub depends on a single F-18 production feed
Buyer-facing decision model
- If timing is the primary risk, weight regional distribution performance
- If overall volume shortfall is the primary risk, weight manufacturer national capacity and allocation history
What formulation and packaging aspects affect which FDG F-18 suppliers you can use?
FDG F-18 supply is not “one-size-fits-all” from a workflow standpoint. Procurement should align with:
- imaging center workflow preferences (pre-measured syringes vs multi-dose vials)
- instrument compatibility for injection (dose preparation steps)
- preferences on concentration and activity per unit volume to match injection protocols
- labeling format and barcoding needs (if required by local systems)
What Orange Book or patent-related issues affect FDG F-18 sourcing?
FDG F-18 is a small-molecule radiopharmaceutical with supply determined primarily by cyclotron and radiopharmaceutical manufacturing capacity rather than long-running patent exclusivity on a market-dominant branded drug. Competitive constraints are more operational than legal: authorized manufacturing capability, quality systems, and distribution capacity.
What generic entry risks exist for FDG F-18?
“Generic entry” is less a traditional small-molecule patent story and more a manufacturing authorization and execution story:
- new entrants must demonstrate production capability, QC release competence, and distribution reliability
- supply constraints can persist even after new approvals due to F-18 production bottlenecks
Key takeaways for selecting FDG F-18 suppliers
- FDG F-18 procurement is dominated by radiopharmaceutical manufacturers and regional dispensing networks tied to F-18 cyclotron capacity.
- The main operational constraint is often F-18 isotope availability and cyclotron scheduling, not FDG synthesis capacity alone.
- Supplier qualification should prioritize delivery windows, activity-on-arrival handling, and allocation contingency during shortages.
- Redundancy strategy should include at least two authorized suppliers covering different distribution hubs or production feeds.
FAQs
1) Can hospitals source FDG F-18 from more than one supplier at the same time?
Yes. Most imaging networks qualify multiple authorized suppliers to manage scheduling variability and shortage risk, subject to local contracting and pharmacy workflow alignment.
2) What is the typical lead time to book FDG F-18 supply?
It depends on radiopharmacy capacity and delivery windows; most suppliers allocate activity on a daily schedule with time-sensitive shipment coordination.
3) How do FDG F-18 shortages typically impact imaging schedules?
Shortages usually force re-planning of PET scan slots, prioritization by clinical need, and substitution of supplier shipments based on activity-on-arrival.
4) What packaging differences should imaging sites confirm before switching FDG F-18 suppliers?
Sites should confirm unit-of-use format, concentration/activity per container, labeling format, and any operational steps affecting injection workflow.
5) What documentation should procurement request from FDG F-18 suppliers?
Procurement typically requests COA or batch release documentation, product specifications, shipping and temperature/handling confirmation, and lot traceability details.
References
- FDA. Radiopharmaceutical Quality. (FDA guidance and quality system resources). https://www.fda.gov/
- FDA. Compounding and radiopharmaceutical oversight resources. https://www.fda.gov/
- SNMMI. FDG and PET radiopharmaceutical usage and operational considerations (society resources). https://snmmi.org/
